文献速递真菌感染细菌感染、耐药与抗菌药物

儿童癌症合并高危发热性中性粒细胞减少症中抢先与经验性抗真菌治疗的疗效:一项随机临床试验

Efficacy of pre-emptive versus empirical antifungal therapy in children with cancer and high-risk febrile neutropenia: a randomized clinical trial.
PubMed 文献 · J Antimicrob Chemother · 2018-01-01

这项前瞻性多中心随机临床试验在智利圣地亚哥五家医院纳入149例癌症合并持续高危发热性中性粒细胞减少症儿童,比较抢先治疗与经验性抗真菌治疗。抢先组76例中32例(42%)接受抗真菌治疗,两组30天总死亡率、侵袭性真菌病相关死亡率及侵袭性真菌病发生率无显著差异,抢先组抗真菌药物使用天数显著减少。

要点

  • 抢先抗真菌治疗与经验性治疗在30天总死亡率上无显著差异(8% vs 5%,P=0.47)。
  • 抢先组抗真菌治疗中位天数6天,经验组11天(P<0.001)。
  • 侵袭性真菌病相关死亡率两组均为3%(P=0.97),侵袭性真菌病发生率均为12%(P=0.92)。

核心结论

  • 在癌症合并发热性中性粒细胞减少症儿童中,抢先抗真菌治疗与经验性抗真菌治疗同样有效,并显著减少抗真菌药物使用。

研究设计与样本

  • 前瞻性、多中心、随机临床试验,在智利圣地亚哥五家医院纳入149例持续高危发热性中性粒细胞减少症儿童,随机分为经验性治疗组73例和抢先治疗组76例;试验注册号RBR-3m9d74。

主要发现

  • 抢先组76例中32例(42%)接受抗真菌治疗;抗真菌治疗中位天数经验组11天 vs 抢先组6天(P<0.001)。
  • 30天总死亡率经验组8% vs 抢先组5%(P=0.47);侵袭性真菌病相关死亡率两组均为3%(P=0.97)。
  • 侵袭性真菌病发生率两组均为12%(P=0.92);发热天数两组均为9天(P=0.76)。
  • 住院天数经验组19天 vs 抢先组17天(P=0.15);需要ICU的比例经验组25% vs 抢先组20%(P=0.47)。

关键数值与推荐

  • 抢先组仅在持续高危发热性中性粒细胞减少症伴预设临床、实验室、影像或微生物学标准时接受抗真菌治疗。
  • 主要终点为随访第30天总死亡率;次要终点包括侵袭性真菌病相关死亡率、发热天数、住院天数、抗真菌药物使用、侵袭性真菌病发生率、初始治疗策略修改需求和ICU需求。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the efficacy of pre-emptive versus empirical antifungal therapy in children with cancer, fever and neutropenia. METHODS: This was a prospective, multicentre, randomized clinical trial. Children presenting with persistent high-risk febrile neutropenia at five hospitals in Santiago, Chile, were randomized to empirical or pre-emptive antifungal therapy. The pre-emptive group received antifungal therapy only if the persistent high-risk febrile neutropenia was accompanied by clinical, laboratory, imaging or microbiological pre-defined criteria. The primary endpoint was overall mortality at day 30 of follow-up. Secondary endpoints included invasive fungal disease (IFD)-related mortality, number of days of fever, days of hospitalization and use of antifungal drugs, percentage of children developing IFD, requiring modification of initial treatment strategy and need for ICU. The trial was registered with Registro Brasileiro de Ensaios Clínicos (ReBEC) under trial number RBR-3m9d74. RESULTS: A total of 149 children were randomized, 73 to empirical therapy and 76 to pre-emptive therapy. Thirty-two out of 76 (42%) children in the pre-emptive group received antifungal therapy. The median duration of antifungal therapy was 11 days in the empirical arm and 6 days in the pre-emptive arm (P < 0.001), with similar overall mortality (8% in the empirical arm and 5% in the pre-emptive arm, P = 0.47). IFD-related mortality was the same in both groups (3%, P = 0.97), as were the percentage of children with IFD (12%, P = 0.92) and the number of days of fever (9, P = 0.76). The number of days of hospitalization was 19 in the empirical arm and 17 in the pre-emptive arm (P = 0.15) and the need for ICU was 25% in the empirical arm and 20% in the pre-emptive arm (P = 0.47). CONCLUSIONS: Pre-emptive antifungal therapy was as effective as empirical antifungal therapy in children with cancer, fever and neutropenia, significantly reducing the use of antifungal drugs.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Santolaya ME, Alvarez AM, Acuña M, et al. Efficacy of pre-emptive versus empirical antifungal therapy in children with cancer and high-risk febrile neutropenia: a randomized clinical trial. J Antimicrob Chemother. 2018. PMID: 30010931. doi:10.1093/jac/dky244

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。